Reirradiation using helical tomotherapy-based hypofractionated stereotactic radiotherapy for 19 brain metastases after the second recurrence of distant brain failure: a case report and literature review.

IF 4 2区 医学 Q2 ONCOLOGY Translational lung cancer research Pub Date : 2025-01-24 Epub Date: 2025-01-22 DOI:10.21037/tlcr-2024-1151
Tao Wang, Hongfu Zhao, Rafal Suwinski, Guanghui Cheng, Wei Guan
{"title":"Reirradiation using helical tomotherapy-based hypofractionated stereotactic radiotherapy for 19 brain metastases after the second recurrence of distant brain failure: a case report and literature review.","authors":"Tao Wang, Hongfu Zhao, Rafal Suwinski, Guanghui Cheng, Wei Guan","doi":"10.21037/tlcr-2024-1151","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A definitive optimal oncologic care regimen for recurrent multiple brain metastases (BMs) has yet to be established, and the accrual of high-quality evidence pertaining to helical tomotherapy-based stereotactic radiotherapy (HT-SRT) in patients with BMs is needed.</p><p><strong>Case description: </strong>We treated a 64-year-old male smoker initially diagnosed with non-small cell lung cancer (NSCLC) with BMs, and the initial schedule involved administering linear accelerator-based hypofractionated stereotactic radiotherapy (Linac-HSRT) targeting 6 intracranial lesions. Further chemotherapy was declined due to intolerance after one cycle of paclitaxel-albumin/carboplatin. Distant brain failure (DBF) and extracranial progression emerged 3 months subsequent to the initial SRT, and helical tomotherapy-based hypofractionated stereotactic radiotherapy (HT-HSRT) was replanned to 4 BMs, while helical tomotherapy-based intensity-modulated radiotherapy was employed for the extracranial lesions. Nevertheless, reirradiation with hippocampal-sparing HT-HSRT and simultaneous memantine approach were imminently delivered for confirmed DBF, as 19 newly identified intact intracranial lesions were observed at 5 months posttreatment. As assessed by the Hopkins Verbal Learning Test Revised Total Recall test, neither severe symptomatic radionecrosis (RN) nor neurocognitive dysfunction has manifested thus far, representing a survival period of 20.5 months. In the literature review, SRT delivery schedule to BMs, strategies for managing recurrent BMs and addressing RN, along with 6 summarized published studies of HT-SRT for BM were discussed.</p><p><strong>Conclusions: </strong>We posit that the administration of repeated SRT for recurrent BMs in a short-term interval may be viable, yet randomized, robust analyses are imperative to ascertain the potential benefits of HT-SRT in preserving neurocognition and confirm the efficacy of memantine and hippocampal avoidance during SRT.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 1","pages":"272-286"},"PeriodicalIF":4.0000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826268/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-2024-1151","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A definitive optimal oncologic care regimen for recurrent multiple brain metastases (BMs) has yet to be established, and the accrual of high-quality evidence pertaining to helical tomotherapy-based stereotactic radiotherapy (HT-SRT) in patients with BMs is needed.

Case description: We treated a 64-year-old male smoker initially diagnosed with non-small cell lung cancer (NSCLC) with BMs, and the initial schedule involved administering linear accelerator-based hypofractionated stereotactic radiotherapy (Linac-HSRT) targeting 6 intracranial lesions. Further chemotherapy was declined due to intolerance after one cycle of paclitaxel-albumin/carboplatin. Distant brain failure (DBF) and extracranial progression emerged 3 months subsequent to the initial SRT, and helical tomotherapy-based hypofractionated stereotactic radiotherapy (HT-HSRT) was replanned to 4 BMs, while helical tomotherapy-based intensity-modulated radiotherapy was employed for the extracranial lesions. Nevertheless, reirradiation with hippocampal-sparing HT-HSRT and simultaneous memantine approach were imminently delivered for confirmed DBF, as 19 newly identified intact intracranial lesions were observed at 5 months posttreatment. As assessed by the Hopkins Verbal Learning Test Revised Total Recall test, neither severe symptomatic radionecrosis (RN) nor neurocognitive dysfunction has manifested thus far, representing a survival period of 20.5 months. In the literature review, SRT delivery schedule to BMs, strategies for managing recurrent BMs and addressing RN, along with 6 summarized published studies of HT-SRT for BM were discussed.

Conclusions: We posit that the administration of repeated SRT for recurrent BMs in a short-term interval may be viable, yet randomized, robust analyses are imperative to ascertain the potential benefits of HT-SRT in preserving neurocognition and confirm the efficacy of memantine and hippocampal avoidance during SRT.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.20
自引率
2.50%
发文量
137
期刊介绍: Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.
期刊最新文献
GNGT1 remodels the tumor microenvironment and promotes immune escape through enhancing tumor stemness and modulating the fibrinogen beta chain-neutrophil extracellular trap signaling axis in lung adenocarcinoma. MS4A15 gene expression as a prognostic marker for clinical outcomes in lung adenocarcinoma. SMARCA4/BRG1-deficient non-small cell lung cancer: clinical, imaging, pathological features, and follow-up results of 23 patients. Association between immunotherapy timing and efficacy in non-small cell lung cancer: a comprehensive analysis at a high-volume specialist centre. Association of systemic therapy with survival among adults with advanced non-small cell lung cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1